Isis Pharmaceuticals Expands Partnership with AstraZeneca
September 11 2015 - 8:30AM
Dow Jones News
Isis Pharmaceuticals Inc. received regulatory clearance Friday
for its partnership with AstraZeneca, by which the companies will
develop antisense drugs for cardiovascular, metabolic and renal
diseases.
Carlsbad, Calif.-based Isis will receive a $65 million upfront
payment from AstraZeneca and is eligible for milestone payments
during the development process in addition to royalties on
potential sales.
The two companies have teamed up before and are in collaboration
on several cancer drugs.
Isis has 38 drugs in its pipeline, and partners with Biogen Inc.
and Sanofi's Genzyme, among others. The company specializes in
RNA-targeted technology to develop antisense drugs. Antisense
treatments are small, DNA- or RNA-like compounds that are
chemically modified to create drugs.
Separately on Friday, AstraZeneca said it bought a Boulder,
Colo., manufacturing facility from Amgen Inc. to support its
growing pipeline.
Terms of the deal weren't disclosed and AstraZeneca said the
acquisition doesn't affect its 2015 guidance. The site is expected
to be operational and licensed for commercial production by late
2017, the company said.
Write to Lisa Beilfuss at lisa.beilfuss@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 11, 2015 08:15 ET (12:15 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Apr 2023 to Apr 2024
